Clovis steals march on AZ with PARP prostate approval

Shares in US-based Clovis Oncology have ticked up after the biotech became the first to get a PARP class drug approved in prostate cancer.

The FDA has approved the company’s Rubraca (rucaparib) as monotherapy for patients with BRCA1/2 mutant castration-resistant disease (mCRPC), after treatment with an androgen receptor-directed therapy and a taxane-based chemotherapy.